
Product Manual


Endothelial Tube Formation Assay (In Vitro Angiogenesis)

Catalog Number

CBA-200

50 assays

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

Angiogenesis, or neovascularization, is the process of generating new blood vessels derived as extensions from the existing vasculature. The principal cells involved are endothelial cells, which line all blood vessels and constitute virtually the entirety of capillaries. Angiogenesis involves multiple steps; to achieve new blood vessel formation, endothelial cells must first escape from their stable location by breaking through the basement membrane. Once this is achieved, endothelial cells migrate toward an angiogenic stimulus such as might be released from tumor cells or wound-associated macrophages. In addition, endothelial cells proliferate to provide the necessary number of cells for making a new vessel. Subsequent to this proliferation, the new outgrowth of endothelial cells needs to reorganize into a three-dimensionally tubular structure. Each of these elements, basement membrane disruption, cell migration, cell proliferation, and tube formation, can be a target for intervention, and each can be tested *in vitro* and *in vivo*.

Several *in vivo* assay systems, including the chick chorioallantoic membrane (CAM) assay, an *in vivo* Matrigel plug assay, and the corneal angiogenesis assay, have been developed that permit a more realistic appraisal of the angiogenic response. However, these assays are time consuming, tedious and require technical specialties.

One quick assessment of angiogenesis is the measurement of the ability of endothelial cells to form three-dimensional structures (tube formation). Endothelial cells form tubes on collagen or fibrin clot coated dishes after several days. Cell Biolabs' Endothelial Tube Formation Assay Kit utilizes ECM (extracellular matrix) gel prepared from Engelbreth–Holm–Swarm (EHS) tumor cells. Endothelial tube formation on ECM gel closely mimics the *in vivo* environment and may be used to test angiogenesis inhibitors before *in vivo* testing.

Cell Biolabs' Endothelial Tube Formation Assay Kit provides a robust system to assess angiogenesis *in vitro*. Tube formation can be achieved within 18 hours. Following staining the tube with the provided fluorescence dye, the extent of tube formation, such as average tube length and branch point, can be quantified through imaging software. Each kit provides sufficient quantities to perform up to 50 assays in 96-well plates.

Kit Components

1. ECM Gel Solution (Part No. 10010): Five 0.5 mL tubes, Ready-To-Use
2. 10X Staining Buffer (Part No. 10011): One 1 mL tube
3. Staining Dye (Part No. 10012): One 50 µL tube of 1 mM Calcein AM in DMSO

Materials Not Supplied

1. Endothelial cells such as HUVEC, HMEC
2. Endothelial cell culture medium
3. 1XPBS
4. 37°C Incubator, 5% CO₂ atmosphere
5. Light microscope

6. Fluorescence microscope
7. (optional) Tube quantification software

Storage

Store all components at -20°C.

Preparation of Reagents

- ECM gel: Thaw overnight on ice or in a frost-free 4°C refrigerator, store the thawed ECM gel solution up to 10 days, do not refreeze. The ECM gel solution will gel rapidly at room temperature. The tube MUST be kept on ice all the time.
- 1X Staining Buffer: Prepare a 1X Staining Buffer by diluting the provided 10X stock 1:10 in dH₂O. Store the diluted solution at room temperature.
- 1X Staining Solution: FRESHLY prepare 1X Staining Buffer by diluting the provided Staining Dye to 1 µM with 1X Staining Buffer. Store 1X Staining Solution at room temperature.

Assay Protocol

I. Tube Formation

1. Thaw ECM gel and prepare 1X Staining Buffer as described above.
2. Add 50 µL of thawed ECM gel solution to each well of a pre-chilled 96-well sterile plate.
Note: Undiluted ECM gel solution is very viscous and quickly gels at room temperature, so it MUST be kept on ice all the time. When pipetting, use a pre-chilled pipette tip to prevent any ECM gel formation during transfer.
3. Incubate 30 minutes to 1 hr at 37°C to allow the ECM solution to form a gel.
4. Harvest endothelial cells and resuspend in desired culture medium containing 0.5-10% serum and your desired angiogenesis mediators at 1-2 x 10⁵ cells/mL.
5. Add 150 µL of cell suspension (1.5-3 x 10⁴ cells) per well onto the solidified ECM gel. Incubate the assay plate at 37°C for 4 to 18 hrs.
6. Examine the endothelial tubes using light microscope in high magnification field. It is possible to visually estimate the extent of tube formation by inspecting the overall tube length and branch points.

II. Fluorescence Labeling

1. Carefully remove medium by gently blotting on paper towels. Be carefully not to disturb endothelial tubes.
2. Gently wash with 100 µL of 1X Staining Buffer and remove the wash as described in step 1.
3. Add 50 µL of 1X Staining Solution per well and incubate 30 min at 37°C.
4. Gently wash with 100 µL of 1X PBS and remove the wash as described in step 1. Repeat this step twice.

5. Examine endothelial cells and tubes using a fluorescence microscope. Acquire several images per well and process them using imaging analysis software such as NIH Image or Image Pro Plus.

Note: Calcein AM-labeled tubular structure is stable for only 1-2 hrs in 1X PBS at 4°C

Example of Results

The following figures demonstrate tube forming results with HUVEC cells using the Endothelial Tube Formation Assay. One should use the data below for reference only. This data should not be used to interpret actual results.




Figure 1. HUVEC Tube Formation on ECM Gel. Left: HUVEC cells on tissue culture plate. **Right:** Tube formation on ECM Gel.

References

1. Grant DS, Kleinman HK, Leblond CP, Inoue S, Chung AE, Martin GR (1985) *Am J Anat* 174:387-398.
2. Jain RK, Schlenger K, Höckel M, Yuan F (1997) *Nat Med* 3:1203-1208.
3. Auerbach R, Auerbach W, Polakowski I (1991) *Pharmacol Ther* 51:1-11.
4. Auerbach R, Akhtar N, Lewis RL, Shinnars BL (2000) *Cancer Metastasis Rev* 19:167-172.
5. Madri JA, Pratt BM, Tucker AM (1988) *J Cell Biol* 106:1375-1384.

Recent Product Citations

1. Liu, H. et al. (2023). Ginsenoside Rg3 inhibits the malignant progression of cervical cancer cell by regulating AKT2 expression. *Heliyon*. **9**(8):e19045. doi: 10.1016/j.heliyon.2023.e19045.
2. Hourri, A. et al. (2023). Suprabasin enhances the invasion, migration, and angiogenic ability of oral squamous cell carcinoma cells under hypoxic conditions. *Oncol Rep*. **49**(5):83. doi: 10.3892/or.2023.8520.
3. Nagashima, Y. et al. (2023). Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats. *Journal of Toxicologic Pathology*. doi: 10.1293/tox.2022-0143.
4. Stellato, M. et al. (2023). The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditions. *Commun Biol*. **6**(1):161. doi: 10.1038/s42003-023-04534-6.

5. Ganesh, V. et al. (2022). Exosome-Based Cell Homing and Angiogenic Differentiation for Dental Pulp Regeneration. *Int J Mol Sci.* **24**(1):466. doi: 10.3390/ijms24010466.
6. Iha, K. et al. (2022). Gastric Cancer Cell-Derived Exosomal GRP78 Enhances Angiogenesis upon Stimulation of Vascular Endothelial Cells. *Curr Issues Mol Biol.* **44**(12):6145-6157. doi: 10.3390/cimb44120419.
7. Zheng, J. et al. (2022). ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D. *Chin J Physiol.* **65**(5):258-265. doi: 10.4103/0304-4920.359795.
8. Yu, B. et al. (2022). miR-29c inhibits metastasis of gastric cancer cells by targeting VEGFA. *J Cancer.* doi: 10.7150/jca.77727.
9. Gong, Y. et al. (2022). Circ_0001897 regulates high glucose-induced angiogenesis and inflammation in retinal microvascular endothelial cells through miR-29c-3p/transforming growth factor beta 2 axis. *Bioengineered.* **13**(5):11694-11705. doi: 10.1080/21655979.2022.2070997.
10. Kieu, T.Q. et al. (2022). Kinetics of LYVE-1-positive M2-like macrophages in developing and repairing dental pulp in vivo and their pro-angiogenic activity in vitro. *Sci Rep.* **12**(1):5176. doi: 10.1038/s41598-022-08987-3.
11. Montero, P. et al. (2022). Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model. *Int. J. Mol. Sci.* **23**(3):1142. doi: 10.3390/ijms23031142.
12. Rofia, B. et al. (2021). Regulatory interplay between Vav1, Syk and β -catenin occurs in lung cancer cells. *Cell Signal.* doi: 10.1016/j.cellsig.2021.110079.
13. Gurel Pekozer, G. et al. (2021). Investigation of Vasculogenesis Inducing Biphasic Scaffolds for Bone Tissue Engineering. *ACS Biomater Sci Eng.* doi: 10.1021/acsbomaterials.0c01071.
14. Zuo, Q. et al. (2021). Aspirin reduces sFlt-1 mediated apoptosis of trophoblast cells in preeclampsia. *Mol Hum Reprod.* doi: 10.1093/molehr/gaaa089.
15. Javadi, J. et al. (2021). Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells. *Cancers (Basel).* **13**(4):655. doi: 10.3390/cancers13040655.
16. Wolcott, K.M. et al. (2020). CD34 positive cells isolated from traumatized human skeletal muscle require the CD34 protein for multi-potential differentiation. *Cell Signal.* doi: 10.1016/j.cellsig.2020.109711.
17. Guerrero, F. et al. (2020). Role of endothelial microvesicles released by p-cresol on endothelial dysfunction. *Sci Rep.* **10**(1):10657. doi: 10.1038/s41598-020-67574-6.
18. Kim, H.K. et al. (2019). RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. *Sci Rep.* **9**(1):19439. doi: 10.1038/s41598-019-55767-7.
19. Cam, M. et al. (2016). Δ Np63 mediates cellular survival and metastasis in canine osteosarcoma. *Oncotarget.* **7**(30):48533-48546. doi: 10.18632/oncotarget.10406.
20. Shirasu, N. et al. (2019). Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies. *Cancer Cell Int.* doi: 10.1186/s12935-019-1034-4.
21. Kitala, D. et al. (2019). Amniotic cells share clusters of differentiation of fibroblasts and keratinocytes, influencing their ability to proliferate and aid in wound healing while impairing their angiogenesis capability. *Eur J Pharmacol.* pii: S0014-2999(19)30148-7. doi: 10.1016/j.ejphar.2019.02.043.

22. Teng, X. et al. (2019). Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. *Diabetologia*. **62**(5):860-872. doi: 10.1007/s00125-019-4828-y.
23. Li, W. et al. (2019). LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway. *Eur J Pharmacol*. **849**:106-114. doi: 10.1016/j.ejphar.2019.01.049.
24. Chen, C.Y. et al. (2018). N-Terminomics identifies HtrA1 cleavage of thrombospondin-1 with generation of a proangiogenic fragment in the polarized retinal pigment epithelial cell model of age-related macular degeneration. *Matrix Biol*. **70**:84-101. doi: 10.1016/j.matbio.2018.03.013.
25. Mouritzen, M.V. et al. (2018). Neurotensin, substance P, and insulin enhance cell migration. *J Pept Sci*. **24**(7):e3093. doi: 10.1002/psc.3093.
26. Kudo, H. et al. (2018). A potential role for the silent information regulator 2 homologue 1 (SIRT1) in periapical periodontitis. *Int Endod J*. **51**(7):747-757. doi: 10.1111/iej.12894.
27. Suda, M., et al. (2017). Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway. *PLoS One*. **12**(8):e0182422. doi: 10.1371/journal.pone.0182422.
28. Bae, W.J. et al. (2017). Lysyl oxidase-mediated VEGF-induced differentiation and angiogenesis in human dental pulp cells. *Int. Endod. J*. doi:10.1111/iej.12796.
29. Katagiri, W. et al. (2017). A defined mix of cytokines mimics conditioned medium from cultures of bone marrow-derived mesenchymal stem cells and elicits bone regeneration. *Cell Prolif*. doi: 10.1111/cpr.12333.
30. Kim, J.Y. et al. (2017). Role of Protein Phosphatase 1 in Angiogenesis and Odontoblastic Differentiation of Human Dental Pulp Cells. *J Endod*. **43**(3):417-424. doi: 10.1016/j.joen.2016.10.013.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
 7758 Arjons Drive
 San Diego, CA 92126
 Worldwide: +1 858-271-6500
 USA Toll-Free: 1-888-CBL-0505
 E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2004-2024: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.